Reunion Neuroscience is committed to creating innovative therapeutic solutions for underserved mental health conditions.

Learn More
What We do

Pushing boundaries

Reunion envisions a day when depression isn’t just managed, it’s curable. That’s why we relentlessly pursue the development of improved, safer, more accessible therapeutics. As an early-stage pharmaceutical company, we’re focused on neuroscience and developing new molecules for people with unmet needs.

Learn More
Our approach

Bold science to transform lives

RE104, our lead candidate, is a proprietary molecule which engages serotonergic receptors in the brain with the potential to induce therapeutically beneficial behavior changes in a variety of psychiatric conditions, including depression, in a manner similar to what has been demonstrated with psilocybin.  Reunion's pipeline—the RE200 group—includes multiple discovery-phase candidates, which seek to improve upon the safety of serotonergic hallucinogens.

About reunion

Experience, meet

Reunion’s team consists of experienced leaders in every aspect of pharmaceutical development. We’re dedicated to trailblazing the path to next-generation therapeutics to create a world where mental and emotional wellbeing are the baseline.

Meet Reunion

Featured News

Featured News

Stay up to date with Reunion news & research.

Dive deeper into Our science